Osmind is a technology, services, and data company focused exclusively on psychiatry. We serve 800+ independent psychiatry practices across 49 states with a purpose-built EHR, software solutions, and managed services. We're a San Francisco–based Series B Public Benefit Corporation backed by DFJ Growth, Future Ventures, General Catalyst, and Y Combinator.
We're growing rapidly and are launching a brand new platform. This is a rare opportunity to shape its technical foundation while making a significant impact on patients, clinicians, and researchers.
\nWe're looking for a hands-on, independent accounting leader to own our accounting function end to end as we bring it in-house. This is a builder's role, not a caretaker's. You will run a clean, timely close across three entities, lead our move onto a true multi-entity platform, and act as a real partner to our VP Finance and leadership team. You will move comfortably between the detail (a reconciliation, a mapping fix) and the big picture (GAAP-compliant, board-ready financials), and you will bring recommendations rather than wait to be asked. We're AI-forward and want someone willing to experiment with AI tools to streamline the function as we build it.
You will work closely with the VP Finance, and will help shape the processes, systems, and eventual team of our accounting organization as it matures from outsourced to in-house.
We want to be honest about the shape of this job:
Osmind is the premier platform for clinicians and researchers advancing new life-saving mental health treatments. Today, mental health disorders are one of the leading causes of death worldwide, especially among young adults, and are tied to shortening lifespans. While there have been developments in new psychiatric medications since the first FDA approval in 1954, today there is a growing movement among clinicians, patients, and researchers who are recognizing the need to accelerate new science.
The Osmind treatment platform is the first and only solution that solves specific challenges faced by neuropsychiatric clinics, spanning general psychiatry and interventional psychiatry (transcranial magnetic stimulation, ketamine, SPRAVATO®, psychedelic medicine, electroconvulsive therapy). The core electronic health record (EHR) technology is precisely developed for interventional treatment workflows and designed to support a strong therapeutic alliance, including journaling tools and assistance with health plan reimbursement, which is a significant access hurdle for millions of patients.
Research from our platform is already helping to set new standards for mental health interventions. For example, in the largest published real-world analysis of ketamine infusion therapy for depression, we teamed up with Stanford University School of Medicine to share findings in the Journal of Affective Disorders (March 2022). We have multiple ongoing research studies leveraging our proprietary real-world data, including an even larger ketamine analysis leveraging machine learning to predict treatment outcomes.
Osmind is a San Francisco–based public benefit corporation led by scientists, technologists, and psychiatrists. We are backed by top investors including DFJ Growth, General Catalyst, Future Ventures, Tiger Global, and Y Combinator.
Location
Philippines
Total raised
$57.2M
Last stage
Series B
Investors
Jimmy Qian
Co-Founder & COO
No applications, no recruiter spam. Just the intro.
A few questions to make sure this role is the right shape for you. Two minutes.
I write the intro, send it to the founder, and handle the back-and-forth.
If they’re a yes, I book the chat. You show up — that’s the whole job-hunt.